These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26086585)

  • 1. Profile. DanDrit Biotech.
    Leire EJ
    Hum Vaccin Immunother; 2015; 11(6):1301. PubMed ID: 26086585
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter from the Editor.
    Ellis R; Weiss A
    Hum Vaccin Immunother; 2015; 11(6):1297. PubMed ID: 26086583
    [No Abstract]   [Full Text] [Related]  

  • 3. Lymphoma vaccine trial: one step forward in long trek.
    Schmidt C
    J Natl Cancer Inst; 2009 Sep; 101(18):1228-9, 1232. PubMed ID: 19738162
    [No Abstract]   [Full Text] [Related]  

  • 4. [Vaccination therapy of melanoma].
    Schuler-Thurner B; Schuler G
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
    [No Abstract]   [Full Text] [Related]  

  • 5. DC-based cancer vaccines: lessons from clinical trials.
    Brody JD; Engleman EG
    Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
    [No Abstract]   [Full Text] [Related]  

  • 6. The first dendritic cell-based therapeutic cancer vaccine is approved by the FDA.
    Hovden AO; Appel S
    Scand J Immunol; 2010 Dec; 72(6):554. PubMed ID: 21044130
    [No Abstract]   [Full Text] [Related]  

  • 7. Special report: vaccines for the treatment of prostate cancer.
    Technol Eval Cent Assess Program Exec Summ; 2010 Apr; 24(6):1-2. PubMed ID: 20575182
    [No Abstract]   [Full Text] [Related]  

  • 8. DC therapy for metastatic melanoma.
    Ingram SB; O'Rourke MG
    Cytotherapy; 2004; 6(2):148-53. PubMed ID: 15203991
    [No Abstract]   [Full Text] [Related]  

  • 9. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
    Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
    Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
    Rosenthal R; Viehl CT; Guller U; Weber WP; Adamina M; Spagnoli GC; Heberer M; Zuber M
    J Am Coll Surg; 2008 Jul; 207(1):95-105. PubMed ID: 18589368
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies.
    Dalgleish AG
    Vaccine; 2011 Nov; 29(47):8501-5. PubMed ID: 21933695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are dysfunctional monocyte-derived dendritic cells in cancer an explanation for cancer vaccine failures?
    Barbuto JA
    Immunotherapy; 2013 Feb; 5(2):105-7. PubMed ID: 23413899
    [No Abstract]   [Full Text] [Related]  

  • 13. Stemline's synthetic multi-peptide cancer vaccine enters Phase 2.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396232
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma.
    Lou E; Marshall J; Aklilu M; Cole D; Chang D; Morse M
    Clin Colorectal Cancer; 2006 Jan; 5(5):368-71. PubMed ID: 16512998
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical applications of dendritic cell cancer vaccines.
    Baar J
    Oncologist; 1999; 4(2):140-4. PubMed ID: 10337385
    [No Abstract]   [Full Text] [Related]  

  • 16. Current issues in delivering DCs for immunotherapy.
    Barratt-Boyes SM; Figdor CG
    Cytotherapy; 2004; 6(2):105-10. PubMed ID: 15203986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shaking Up Biotech/Pharma: Can Cues Be Taken from the Tech Industry?
    Wang CK
    SLAS Technol; 2017 Jun; 22(3):233-236. PubMed ID: 28298148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current approaches in ovarian cancer vaccines.
    Reinartz S; Wagner U
    Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive phase 2 results for immatics colorectal cancer vaccine.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Mar; 8(3):282. PubMed ID: 22418877
    [No Abstract]   [Full Text] [Related]  

  • 20. Technology evaluation: HSPPC-96, antigenics.
    Minev BR
    Curr Opin Mol Ther; 2003 Dec; 5(6):680-7. PubMed ID: 14755896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.